SEC Form 4 · Updated Daily
REPL
— REPLIMUNE GROUP, INC. OwnershipInsider and institutional ownership derived from SEC Form 4 filings. Click any owner to see their holdings across every company they’ve filed on, and how their position has changed over time.
Current Reporting Owners
| Owner | Role | Shares Owned | As Of | Last Activity |
|---|---|---|---|---|
| BAKER FELIX | 10%+ Owner · Director | 10,116,095 | 2025-03-05 | — |
| 667, L.P. | 10%+ Owner · Director | 10,116,095 | 2025-03-05 | — |
| BAKER JULIAN | 10%+ Owner · Director | 10,116,095 | 2025-03-05 | — |
| BAKER BROS. ADVISORS LP | 10%+ Owner · Director | 10,116,095 | 2025-03-05 | — |
| Baker Bros. Advisors (GP) LLC | 10%+ Owner · Director | 10,116,095 | 2025-03-05 | — |
| Baker Brothers Life Sciences LP | 10%+ Owner · Director | 10,116,095 | 2025-03-05 | — |
| Paster Anne-Mari | 10%+ Owner | 4,854,783 | 2018-07-24 | C |
| Lim Richard J. | 10%+ Owner | 4,854,783 | 2018-07-24 | C |
| Omega Fund IV G.P. Manager, Ltd. | 10%+ Owner | 4,779,880 | 2022-03-14 | M |
| Omega Fund IV, L.P. | 10%+ Owner | 4,779,880 | 2022-03-14 | M |
| Omega Fund IV GP, L.P. | 10%+ Owner | 4,779,880 | 2022-03-14 | M |
| Stampacchia Otello | 10%+ Owner | 4,779,880 | 2022-03-14 | M |
| Slootweg Hugo Alexander | Director | 4,721,449 | 2018-07-24 | P |
| Forbion Capital Fund III Cooperatief U.A. | 10%+ Owner | 4,721,449 | 2018-07-24 | P |
| Atlas Venture Associates X, LLC | 10%+ Owner | 4,453,386 | 2018-07-24 | C |
| ATLAS VENTURE ASSOCIATES X, L.P. | 10%+ Owner | 4,453,386 | 2018-07-24 | C |
| Bain Capital Life Sciences Partners, LP | 10%+ Owner | 2,838,968 | 2018-07-24 | P |
| BCIP Life Sciences Associates, LP | 10%+ Owner | 2,838,968 | 2018-07-24 | P |
| Bain Capital Life Sciences Investors, LLC | 10%+ Owner | 2,838,968 | 2018-07-24 | P |
| Koppel Adam | 10%+ Owner · Director | 2,838,968 | 2018-07-24 | P |
| Schwartz Jeffrey Lawrence | 10%+ Owner | 2,838,968 | 2018-07-24 | P |
| Bain Capital Life Sciences Fund, L.P. | 10%+ Owner | 2,838,968 | 2018-07-24 | P |
| Atlas Venture Fund X, L.P. | 10%+ Owner | 2,486,296 | 2020-09-15 | J |
| Coffin Robert | Director | 1,821,872 | 2024-05-16 | S |
| Astley-Sparke Philip | Director | 1,362,414 | 2026-08-20 | G |
| Atlas Venture Opportunity Fund I, L.P. | Reporting Owner | 1,100,000 | 2019-11-18 | — |
| Atlas Venture Associates Opportunity I, LLC | Reporting Owner | 1,100,000 | 2019-11-18 | — |
| Atlas Venture Associates Opportunity I, L.P. | Reporting Owner | 1,100,000 | 2019-11-18 | — |
| Rhodes Jason P | Director | 946,000 | 2021-01-26 | S |
| Green Jeremy | Director | 779,655 | 2018-07-24 | C |
| Redmile Group, LLC | Director | 779,655 | 2018-07-24 | C |
| Love Colin | Officer | 777,345 | 2024-05-16 | S |
| Patel Sushil | Director · Officer | 708,151 | 2026-08-10 | S |
| Esposito Pamela | Officer | 268,794 | 2023-09-11 | M |
| Xynos Konstantinos | Officer | 224,215 | 2026-08-10 | S |
| Hill Emily Luisa | Officer | 215,852 | 2026-08-17 | S |
| Sarchi Christopher | Officer | 180,962 | 2026-06-01 | S |
| Lewis Tanya | Officer | 136,110 | 2023-06-13 | S |
| Franchi Jean M. | Officer | 128,748 | 2023-05-16 | S |
| Schwendenman Andrew | Officer | 99,425 | 2026-08-10 | S |
| Kaufman Howard | Officer | 58,067 | 2019-11-26 | M |
| Pirzkall Andrea | Officer | 21,500 | 2021-04-01 | A |
| SLATTERY JOSEPH P | Director | 11,867 | 2020-12-08 | M |
| Dhingra Kapil | Director | 3,169 | 2025-12-09 | M |
Recent Filings
| Date | Owner | Activity | Shares | Price | Owned After |
|---|---|---|---|---|---|
| 2026-08-20 | Astley-Sparke Philip | Gift | 50,000 | $0.00 | 1,362,414 |
| 2026-08-17 | Hill Emily Luisa | Open-market sale | 9,256 | $14.28 | 215,852 |
| 2026-08-11 | BAKER JULIAN | Open-market buy (derivative) | 2,609,946 | $12.06 | 2,609,946 |
| 2026-08-11 | BAKER JULIAN | Open-market buy (derivative) | 126,394 | $12.06 | 126,394 |
| 2026-08-11 | BAKER FELIX | Open-market buy (derivative) | 2,609,946 | $12.06 | 2,609,946 |
| 2026-08-11 | BAKER FELIX | Open-market buy (derivative) | 126,394 | $12.06 | 126,394 |
| 2026-08-11 | Baker Brothers Life Sciences LP | Open-market buy (derivative) | 2,609,946 | $12.06 | 2,609,946 |
| 2026-08-11 | Baker Brothers Life Sciences LP | Open-market buy (derivative) | 126,394 | $12.06 | 126,394 |
| 2026-08-11 | 667, L.P. | Open-market buy (derivative) | 2,609,946 | $12.06 | 2,609,946 |
| 2026-08-11 | 667, L.P. | Open-market buy (derivative) | 126,394 | $12.06 | 126,394 |
| 2026-08-11 | Baker Bros. Advisors (GP) LLC | Open-market buy (derivative) | 2,609,946 | $12.06 | 2,609,946 |
| 2026-08-11 | Baker Bros. Advisors (GP) LLC | Open-market buy (derivative) | 126,394 | $12.06 | 126,394 |
| 2026-08-11 | BAKER BROS. ADVISORS LP | Open-market buy (derivative) | 2,609,946 | $12.06 | 2,609,946 |
| 2026-08-11 | BAKER BROS. ADVISORS LP | Open-market buy (derivative) | 126,394 | $12.06 | 126,394 |
| 2026-08-10 | Schwendenman Andrew | Open-market sale | 7,632 | $12.97 | 99,425 |
| 2026-08-10 | Xynos Konstantinos | Open-market sale | 11,447 | $12.97 | 224,215 |
| 2026-08-10 | Hill Emily Luisa | Open-market sale | 11,448 | $12.97 | 225,108 |
| 2026-08-10 | Patel Sushil | Open-market sale | 39,341 | $12.97 | 708,151 |
| 2026-06-01 | Sarchi Christopher | Open-market sale | 12,000 | $9.24 | 180,962 |
| 2026-05-18 | Hill Emily Luisa | Open-market sale | 7,812 | $5.08 | 236,556 |
| 2026-05-18 | Patel Sushil | Open-market sale | 37,324 | $5.08 | 747,492 |
| 2026-05-18 | Astley-Sparke Philip | Open-market sale | 17,657 | $5.08 | 1,412,414 |
| 2026-05-18 | Sarchi Christopher | Open-market sale | 8,626 | $5.08 | 192,962 |
| 2026-05-18 | Schwendenman Andrew | Open-market sale | 7,894 | $5.08 | 107,057 |
| 2026-05-18 | Xynos Konstantinos | Open-market sale | 14,023 | $5.08 | 235,662 |
| 2026-04-02 | Sarchi Christopher | Open-market sale | 6,500 | $8.01 | 151,588 |
| 2026-04-01 | Weinand Dieter | Grant / award (derivative) | 44,500 | $0.00 | 44,500 |
| 2026-04-01 | Hill Emily Luisa | Grant / award (derivative) | 75,000 | $0.00 | 75,000 |
| 2026-04-01 | Hill Emily Luisa | Grant / award | 50,000 | $0.00 | 244,368 |
| 2026-04-01 | Peeples-Dyer Veleka | Grant / award (derivative) | 44,500 | $0.00 | 44,500 |
| 2026-04-01 | SLATTERY JOSEPH P | Grant / award (derivative) | 44,500 | $0.00 | 44,500 |
| 2026-04-01 | Pucci Paolo | Grant / award (derivative) | 44,500 | $0.00 | 44,500 |
| 2026-04-01 | Dhingra Kapil | Grant / award (derivative) | 44,500 | $0.00 | 44,500 |
| 2026-04-01 | Patel Sushil | Grant / award (derivative) | 376,860 | $0.00 | 376,860 |
| 2026-04-01 | Patel Sushil | Grant / award | 251,240 | $0.00 | 784,816 |
| 2026-04-01 | Schwendenman Andrew | Grant / award (derivative) | 55,000 | $0.00 | 55,000 |
| 2026-04-01 | Schwendenman Andrew | Grant / award | 36,667 | $0.00 | 114,951 |
| 2026-04-01 | Balachandran Madhavan | Grant / award (derivative) | 44,500 | $0.00 | 44,500 |
| 2026-04-01 | Xynos Konstantinos | Grant / award (derivative) | 75,000 | $0.00 | 75,000 |
| 2026-04-01 | Xynos Konstantinos | Grant / award | 50,000 | $0.00 | 249,685 |
Source: SEC EDGAR Form 4 filings. For informational purposes only — not investment advice.